Citations to this article
Citation Information: JCI Insight. 2018;3(8):e99488. https://doi.org/10.1172/jci.insight.99488.
Engineered T cells targeting E7 mediate regression of human papillomavirus cancers in a murine model
Abstract
T cell receptor (TCR) T cell therapy is a promising cancer treatment modality. However, its successful development for epithelial cancers may depend on the identification of high-avidity TCRs directed against tumor-restricted target antigens. The human papillomavirus (HPV) E7 antigen is an attractive therapeutic target that is constitutively expressed by HPV+ cancers but not by healthy tissues. It is unknown if genetically engineered TCR T cells that target E7 can mediate regression of HPV+ cancers. We identified an HPV-16 E7-specific, HLA-A*02:01-restricted TCR from a uterine cervix biopsy from a woman with cervical intraepithelial neoplasia. This TCR demonstrated high functional avidity, with CD8 coreceptor–independent tumor targeting. Human T cells transduced to express the TCR specifically recognized and killed HPV-16+ cervical and oropharyngeal cancer cell lines and mediated regression of established HPV-16+ human cervical cancer tumors in a mouse model. These findings support the therapeutic potential of this approach and established the basis for an E7 TCR gene therapy clinical trial in patients with metastatic HPV+ cancers (NCT02858310).
Authors
Benjamin Y. Jin, Tracy E. Campbell, Lindsey M. Draper, Sanja Stevanović, Bianca Weissbrich, Zhiya Yu, Nicholas P. Restifo, Steven A. Rosenberg, Cornelia L. Trimble, Christian S. Hinrichs
Total citations by year
Citations to this article in year 2022 (16)
| Title and authors | Publication | Year |
|---|---|---|
|
Cancer Therapy With TCR-Engineered T Cells: Current Strategies, Challenges, and Prospects
P Shafer, L Kelly, V Hoyos |
Frontiers in immunology | 2022 |
|
A TCR mimic monoclonal antibody for the HPV-16 E7-epitope p11-19/HLA-A*02:01 complex
T Dao, S Mun, T Korontsvit, A Khan, M Pohl, T White, M Klatt, D Andrew, I Lorenz, D Scheinberg, Z Zheng |
PloS one | 2022 |
|
Determining if T cell antigens are naturally processed and presented on HLA class I molecules
J Friedman, S Gunti, M Lee, K Bai, C Hinrichs, C Allen |
BMC Immunology | 2022 |
|
TCR engineered T cells for solid tumor immunotherapy
Y Zhang, Z Liu, W Wei, Y Li |
Experimental Hematology and Oncology | 2022 |
|
Gene Therapy for Malignant and Benign Gynaecological Disorders: A Systematic Review of an Emerging Success Story
Drakopoulou E, Anagnou NP, Pappa KI |
Cancers | 2022 |
|
Development and therapeutic manipulation of the head and neck cancer tumor environment to improve clinical outcomes.
Duhen T, Gough MJ, Leidner RS, Stanton SE |
2022 | |
|
Durable response in a patient with recurrent respiratory papillomatosis treated with immune checkpoint blockade.
Bai K, Norberg SM, Sievers C, Meyer T, Friedman J, Hinrichs C, Allen CT |
Head & Neck | 2022 |
|
Identification of novel HLA-A*11:01-restricted HPV16 E6/E7 epitopes and T-cell receptors for HPV-related cancer immunotherapy
Xiong C, Huang L, Kou H, Wang C, Zeng X, Sun H, Liu S, Wu B, Li J, Wang X, Wang Z, Chen L |
Journal for ImmunoTherapy of Cancer | 2022 |
|
The association of cervicovaginal Langerhans cells with clearance of human papillomavirus.
Dai W, Gui L, Du H, Li S, Wu R |
Frontiers in immunology | 2022 |
|
Rapid generation of genetically engineered T cells for the treatment of virus‐related cancers
Jiang J, Xia M, Zhang L, Chen X, Zhao Y, Zeng C, Yang H, Liang P, Li G, Li N, Qi H, Wei T, Ren L |
Cancer Science | 2022 |
|
Immune landscape and immunotherapy for penile cancer
Tang Y, Hu X, Wu K, Li X |
Frontiers in immunology | 2022 |
|
Non-viral precision T cell receptor replacement for personalized cell therapy
Foy SP, Jacoby K, Bota DA, Hunter T, Pan Z, Stawiski E, Ma Y, Lu W, Peng S, Wang CL, Yuen B, Dalmas O, Heeringa K, Sennino B, Conroy A, Bethune MT, Mende I, White W, Kukreja M, Gunturu S, Humphrey E, Hussaini A, An D, Litterman AJ, Quach BB, Ng AH, Lu Y, Smith C, Campbell KM, Anaya D, Skrdlant L, Huang EY, Mendoza V, Mathur J, Dengler L, Purandare B, Moot R, Yi MC, Funke R, Sibley A, Stallings-Schmitt T, Oh DY, Chmielowski B, Abedi M, Yuan Y, Sosman JA, Lee SM, Schoenfeld AJ, Baltimore D, Heath JR, Franzusoff A, Ribas A, Rao AV, Mandl SJ |
Nature | 2022 |
|
Exploiting the immunogenic potential of standard of care radiation or cisplatin therapy in preclinical models of HPV-associated malignancies
Kowalczyk JT, Fabian KP, Padget MR, Lopez DC, Hoke AT, Allen CT, Hermsen M, London, NR Jr, Hodge JW |
Journal for ImmunoTherapy of Cancer | 2022 |
|
Scaling up and scaling out: Advances and challenges in manufacturing engineered T cell therapies
Song HW, Somerville RP, Stroncek DF, Highfill SL |
International Reviews of Immunology | 2022 |
|
Towards Novel Gene and Cell Therapy Approaches for Cervical Cancer
Polten R, Kutle I, Hachenberg J, Klapdor R, Morgan M, Schambach A |
Cancers | 2022 |
|
Engineered T Cell Therapy for Viral and Non-viral Epithelial Cancers
Norberg SM, Hinrichs CS |
Cancer Cell | 2022 |
